Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Net Cash Flow: 2019-2024

Historic Net Cash Flow for Centessa Pharmaceuticals (CNTA) over the last 6 years, with Dec 2024 value amounting to $254.0 million.

  • Centessa Pharmaceuticals' Net Cash Flow fell 97.38% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$345.1 million, marking a year-over-year decrease of 252.82%. This contributed to the annual value of $254.0 million for FY2024, which is 195.39% up from last year.
  • Centessa Pharmaceuticals' Net Cash Flow amounted to $254.0 million in FY2024, which was up 195.39% from -$266.2 million recorded in FY2023.
  • Over the past 5 years, Centessa Pharmaceuticals' Net Cash Flow peaked at $588.3 million during FY2021, and registered a low of -$266.2 million during FY2023.
  • Moreover, its 3-year median value for Net Cash Flow was -$201.0 million (2022), whereas its average is -$71.1 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first crashed by 391.45% in 2020, then surged by 6,447.58% in 2021.
  • Over the past 5 years, Centessa Pharmaceuticals' Net Cash Flow (Yearly) stood at -$9.3 million in 2020, then skyrocketed by 6,447.58% to $588.3 million in 2021, then slumped by 134.17% to -$201.0 million in 2022, then slumped by 32.44% to -$266.2 million in 2023, then spiked by 195.39% to $254.0 million in 2024.